/stocks — the workspaceLOADING
ProQR Therapeutics N.V. (PRQR) is a pharmaceutical preparations company. 5 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
What’s behind PRQR’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
No recent 10-K / 10-Q / 8-K filings found.
Has PRQR been issuing shares? Offering history →
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
A plain-English read on PRQR plus an auto-SWOT — built from PRQR's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate PRQR using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Projected from PRQR's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentPRQR files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
Total return including reinvested dividends, from PRQR’s adjusted closing prices. Past return is not a forecast and not investment advice.
| Filius BartDirector | BUY | $258K | view → |
| de Boer Daniel AntonChief Executive Officer | BUY | $261K | view → |
| de Boer Daniel AntonChief Executive Officer | BUY | $239K | view → |
| Filius BartDirector | BUY | $231K | view → |
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.